Understanding Obstructive Sleep Apnoea/Hypopnoea Syndrome

Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a condition that causes interrupted breathing during sleep due to a blockage in the airway. This can lead to a range of health problems, including daytime somnolence, respiratory acidosis, and hypertension. There are several predisposing factors for OSAHS, including obesity, macroglossia, large tonsils, and Marfan’s syndrome. Partners of those with OSAHS often complain of excessive snoring and periods of apnoea.

To assess sleepiness, patients may complete the Epworth Sleepiness Scale questionnaire, and undergo the Multiple Sleep Latency Test (MSLT) to measure the time it takes to fall asleep in a dark room. Diagnostic tests for OSAHS include sleep studies (polysomnography), which measure a range of physiological factors such as EEG, respiratory airflow, thoraco-abdominal movement, snoring, and pulse oximetry.

Management of OSAHS includes weight loss and the use of continuous positive airway pressure (CPAP) as a first-line treatment for moderate or severe cases. Intra-oral devices, such as mandibular advancement, may be used if CPAP is not tolerated or for patients with mild OSAHS without daytime sleepiness. It is important to inform the DVLA if OSAHS is causing excessive daytime sleepiness. While there is limited evidence to support the use of pharmacological agents, they may be considered in certain cases.

One of the few interventions that has been proven to increase survival in COPD after quitting smoking is long-term oxygen therapy (LTOT). Patients with a pO2 level below 7.3 kPa should be offered LTOT, as well as those with a pO2 level between 7.3 – 8 kPa who have secondary polycythemia, nocturnal hypoxemia, peripheral edema, or pulmonary hypertension.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

If an ex-smoker experiences shortness of breath, weight loss, and hyponatremia, urgent investigation for lung cancer is necessary, even if their chest x-ray appears normal. This recommendation is in line with the current guidelines from NICE. Although gastrointestinal cancer cannot be ruled out, the absence of chronic blood loss indicated by a normal MCV is not entirely conclusive.

Referral Guidelines for Lung Cancer

Lung cancer is a serious condition that requires prompt diagnosis and treatment. The 2015 NICE cancer referral guidelines provide clear advice on when to refer patients for suspected lung cancer. According to these guidelines, patients should be referred using a suspected cancer pathway referral for an appointment within 2 weeks if they have chest x-ray findings that suggest lung cancer or are aged 40 and over with unexplained haemoptysis.

For patients aged 40 and over who have 2 or more unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss, an urgent chest x-ray should be offered within 2 weeks to assess for lung cancer. This recommendation also applies to patients who have ever smoked and have 1 or more of these unexplained symptoms.

In addition, patients aged 40 and over with persistent or recurrent chest infection, finger clubbing, supraclavicular lymphadenopathy or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or thrombocytosis should be considered for an urgent chest x-ray within 2 weeks to assess for lung cancer.

Overall, these guidelines provide clear and specific recommendations for healthcare professionals to identify and refer patients with suspected lung cancer for prompt diagnosis and treatment.

Pink skin and mucosae are indicative of carbon monoxide poisoning.

Carbon monoxide poisoning occurs when carbon monoxide binds to haemoglobin and myoglobin, leading to tissue hypoxia. Symptoms include headache, nausea, vomiting, vertigo, confusion, and in severe cases, pink skin and mucosae, hyperpyrexia, arrhythmias, extrapyramidal features, coma, and death. Diagnosis is made through measuring carboxyhaemoglobin levels in arterial or venous blood gas. Treatment involves administering 100% high-flow oxygen via a non-rebreather mask for at least six hours, with hyperbaric oxygen therapy considered for more severe cases.

Understanding Stridor and its Association with Lung Cancer

Stridor is a respiratory sound characterized by a loud, harsh, and high-pitched noise. It is usually heard during inspiration and is caused by a partial obstruction of the airway, particularly in the trachea, larynx, or pharynx. In severe cases of upper airway obstruction, stridor may also occur during expiration, indicating tracheal or bronchial obstruction within the thoracic cavity.

Lung cancer is one of the conditions that can cause stridor, particularly small cell carcinomas that grow rapidly and metastasize to mediastinal lymph nodes early in the disease’s course. Patients with lung cancer may present with large intra-thoracic tumors, making it difficult to distinguish the primary tumor from lymph node metastases. The pressure on mediastinal structures can cause various symptoms, including hoarseness, hemi-diaphragm paralysis, dysphagia, and stridor due to compression of the major airways. Understanding the association between stridor and lung cancer can help in the early detection and management of the disease.

Step-Up Treatment for COPD Patients

When a patient with COPD is only taking salbutamol inhalers and their FEV1 is less than 50%, it may be necessary to step up their treatment. One option is to add a LABA+ICS, which can help improve lung function and reduce symptoms. However, it’s important to note that a LAMA should not be used in combination with an ICS. While adding a regular ICS may be considered in asthma treatment, it is not typically part of the step-up approach for COPD. Additionally, a SAMA can be an alternative to salbutamol inhalers, but it is not intended as a step-up treatment. By carefully considering the best options for each patient, healthcare providers can help manage COPD symptoms and improve quality of life.

Bronchiectasis as a Possible Diagnosis for Chronic Non-Productive Cough

Consider bronchiectasis as a possible diagnosis for a patient with a chronic non-productive cough, especially if the patient is a non-smoker. While other diagnoses are also possible, bronchiectasis is more likely if the patient doesn’t exhibit symptoms such as night sweats, weight loss, or the growth of Pseudomonas. It is important to note that a chest X-ray may not always show abnormalities in patients with bronchiectasis, and a CT-scan is often necessary for an accurate diagnosis. Therefore, if a patient presents with a chronic non-productive cough, bronchiectasis should be considered as a possible diagnosis, particularly in non-smokers.

Diagnostic Tests for COPD

In addition to spirometry, it is recommended that patients with COPD undergo several diagnostic tests at the time of diagnosis. These tests include a chest x-ray to rule out other potential lung pathologies, a full blood count to assess for anemia or polycythemia, and a calculation of body mass index.

Depending on the patient’s history and examination findings, other diagnostic tests may be necessary. For example, if asthma is suspected, serial peak flow measurements may be indicated. If signs or symptoms of cor pulmonale are present, an ECG or echocardiogram may be necessary. By conducting these diagnostic tests, healthcare professionals can accurately diagnose and manage COPD in their patients.

Most Likely Cause of Bronchospasm in a Patient with Asthma

Examiners often use terms like most likely to test a candidate’s ability to reason. In primary care, where there may be multiple causes, prioritizing treatment options is crucial. In a patient with a history of asthma experiencing bronchospasm, propranolol is the most likely cause, and its use should be avoided. While bronchospasm is reported in aspirin-sensitive patients and paradoxical bronchospasm in some patients treated with salmeterol, beta-blockers like propranolol can precipitate bronchospasm and should be avoided in patients with asthma.

According to the British National Formulary, beta-blockers should be avoided in patients with a history of asthma. However, in some cases, a cardioselective beta-blocker may be necessary for a co-existing condition like heart failure or following a myocardial infarction. In such situations, a specialist should initiate treatment with a low dose of a cardioselective beta-blocker like atenolol, bisoprolol fumarate, metoprolol tartrate, nebivolol, or acebutolol. These drugs have a lesser effect on airways resistance but are not free of this side-effect.

ACE inhibitors like ramipril are inhibitors of the metabolism of bradykinin and can cause cough. Bronchospasm is also reported as an adverse event associated with ACE inhibition, although it is very rare.

Consider Pulmonary Fibrosis in Patients with Persistent Breathlessness and Clubbing

It is crucial to consider a diagnosis of pulmonary fibrosis in patients who present with persistent breathlessness, dry cough, bilateral inspiratory crackles, and clubbing of the fingers. While COPD may be a possibility, it would not explain the presence of clubbing. Heart failure typically presents with other features such as orthopnoea, peripheral oedema, and a raised JVP. Bronchiectasis usually has a productive cough, and a pulmonary embolism typically presents more acutely with chest pain and without clubbing or bi-basal crackles. Therefore, it is essential to consider pulmonary fibrosis as a potential diagnosis in patients with these symptoms. Proper diagnosis and treatment can help improve patient outcomes and quality of life.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

Understanding Pulmonary Function Tests

Pulmonary function tests are a useful tool in determining whether a respiratory disease is obstructive or restrictive. These tests measure various aspects of lung function, such as forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). By analyzing the results of these tests, doctors can diagnose and monitor conditions such as asthma, COPD, pulmonary fibrosis, and neuromuscular disorders.

In obstructive lung diseases, such as asthma and COPD, the FEV1 is significantly reduced, while the FVC may be reduced or normal. The FEV1% (FEV1/FVC) is also reduced. On the other hand, in restrictive lung diseases, such as pulmonary fibrosis and asbestosis, the FEV1 is reduced, but the FVC is significantly reduced. The FEV1% (FEV1/FVC) may be normal or increased.

It is important to note that there are many conditions that can affect lung function, and pulmonary function tests are just one tool in diagnosing and managing respiratory diseases. However, understanding the results of these tests can provide valuable information for both patients and healthcare providers.

A provoked pulmonary embolism, which occurred after surgery and immobilisation in a middle-aged man, typically requires treatment for at least 3 months. However, the duration of treatment may need to be extended or specialist referral may be necessary depending on the patient’s leg and respiratory symptoms. Indefinite anticoagulation is not recommended unless the problem is recurrent or the patient has thrombophilia. Referral to a haematologist is also not necessary unless the treatment is unsuccessful or the patient experiences further thrombosis issues. Anticoagulation for 6 months may be considered for unprovoked pulmonary embolism, but in this case, the patient’s condition was provoked by surgery and immobilisation.

Management of Pulmonary Embolism

Pulmonary embolism (PE) is a serious condition that requires prompt management. The National Institute for Health and Care Excellence (NICE) updated their guidelines on the management of venous thromboembolism (VTE) in 2020, with some key changes. One of the significant changes is the recommendation to use direct oral anticoagulants (DOACs) as the first-line treatment for most people with VTE, including those with active cancer. Another change is the increasing use of outpatient treatment for low-risk PE patients, determined by a validated risk stratification tool.

Anticoagulant therapy is the cornerstone of VTE management. The guidelines recommend using apixaban or rivaroxaban as the first-line treatment for PE, followed by LMWH, dabigatran, edoxaban, or a vitamin K antagonist (VKA) if necessary. For patients with active cancer, DOACs are now recommended instead of LMWH. The length of anticoagulation depends on whether the VTE was provoked or unprovoked, with treatment typically lasting for at least three months. Patients with unprovoked VTE may continue treatment for up to six months, depending on their risk of recurrence and bleeding.

In cases of haemodynamic instability, thrombolysis is recommended as the first-line treatment for massive PE with circulatory failure. Other invasive approaches may also be considered where appropriate facilities exist. Patients who have repeat pulmonary embolisms, despite adequate anticoagulation, may be considered for inferior vena cava (IVC) filters. However, the evidence base for IVC filter use is weak, and further studies are needed.

For this patient with pre-existing asthma, an immediate or delayed antibiotic prescription should be considered due to the higher risk of complications. The first-line antibiotic for acute bronchitis is oral doxycycline, unless the patient is pregnant or a child. As this patient has normal observations and no focal respiratory signs, same-day admission is not necessary, and treatment can be provided in the community without intravenous antibiotics or oxygen.

Reassuring the patient and prescribing carbocisteine is not recommended as mucolytics are not effective for managing acute cough caused by acute bronchitis. Administering IM amoxicillin is also not appropriate as doxycycline is the recommended first-choice antibiotic for this condition, and IM is an invasive route that is unnecessary for this patient who can swallow.

Understanding Acute Bronchitis

Acute bronchitis is a chest infection that is typically self-limiting and caused by inflammation of the trachea and major bronchi. This results in swollen airways and the production of sputum. The condition usually resolves within three weeks, but some patients may experience a cough for longer. Viral infections are the leading cause of acute bronchitis, with most cases occurring in the autumn or winter.

Symptoms of acute bronchitis include a sudden onset of cough, sore throat, runny nose, and wheezing. While most patients have a normal chest examination, some may experience a low-grade fever or wheezing. It is important to differentiate acute bronchitis from pneumonia, which may present with sputum, wheezing, and breathlessness.

Acute bronchitis is typically diagnosed based on clinical presentation, but CRP testing may be used to guide antibiotic therapy. Management of acute bronchitis includes analgesia, good fluid intake, and consideration of antibiotic therapy for patients who are systemically unwell, have pre-existing co-morbidities, or have a CRP level indicating the need for antibiotics. Doxycycline is the first-line antibiotic recommended by NICE Clinical Knowledge Summaries/BNF, but it cannot be used in children or pregnant women. Alternatives include amoxicillin.

British Thoracic Society Guidelines for Asthma Management

The British Thoracic Society has provided guidelines for the management of asthma, which is a potentially life-threatening condition. To categorize the severity of an acute asthma attack and guide management, parameters such as respiratory rate, pulse rate, and peak flow rate are essential. For instance, a peak flow rate of just over 33% of the patient’s best is considered an ‘acute severe’ attack.

An ‘acute severe’ attack is defined as any one of the following: peak expiratory flow rate of 33-50% best or predicted, respiratory rate of 25 or more per minute, heart rate of 110 or more beats per minute, or inability to complete sentences in one breath. On the other hand, a ‘life-threatening’ attack is defined as any of the following features in a patient with severe asthma: peak expiratory flow rate <33% best or predicted, oxygen saturation less than 92%, PaO2 of <8 kPa, normal PaCO2, silent chest, cyanosis, poor respiratory effort, arrhythmia, or exhaustion/altered conscious level. It is crucial to follow these guidelines to ensure appropriate management of asthma and prevent life-threatening complications.

Understanding Inhaled Corticosteroids: Uses, Benefits, and Side Effects

Inhaled corticosteroids are commonly used to manage reversible and irreversible airways disease. They can also help distinguish between asthma and chronic obstructive pulmonary disease (COPD) when used for 3-4 weeks. If there is clear improvement over this period, it suggests asthma. In COPD, inhaled corticosteroids can reduce exacerbations when combined with an inhaled long-acting beta2 agonist. However, it’s important to use corticosteroid inhalers regularly for maximum benefit, and improvement of symptoms usually occurs within 3-7 days.

While inhaled corticosteroids are generally safe, high doses used for prolonged periods can induce adrenal suppression. However, in children, growth restriction associated with systemic corticosteroid therapy and high dose inhaled corticosteroids doesn’t seem to occur with recommended doses. Although initial growth velocity may be reduced, there appears to be no effect on achieving normal adult height. The most common side-effects are hoarseness, throat irritation, and candidiasis of the mouth or throat. Candidiasis can be reduced by using a spacer device and rinsing the mouth with water or cleaning a child’s teeth after taking a dose. Paradoxical bronchospasm is a rare occurrence.

In summary, inhaled corticosteroids are a valuable tool in managing airways disease, but it’s important to use them as directed and be aware of potential side-effects. With proper use, they can provide significant relief and improve quality of life for those with asthma and COPD.

Guidelines for Safe Air Travel

When it comes to air travel, there are certain guidelines that need to be followed to ensure a safe journey. One of the most important factors is the ability to walk 50 meters on level ground or climb one flight of stairs without experiencing shortness of breath. This is usually indicative of being able to fly without any issues.

Another important consideration is the hypoxic challenge test, which mimics the conditions on the plane. If the PaO2 level is less than 55 mmHg, it is not recommended to fly. At rest, the oxygen saturation level should be 95% or higher.

If you have had a pneumothorax, it is recommended to wait for at least two weeks before considering air travel. This is especially important if the pneumothorax has been conservatively managed. Only after there is evidence that the pneumothorax has resolved should you consider flying.

By following these guidelines, you can ensure a safe and comfortable air travel experience.

Erythema Nodosum and Sarcoidosis: An Overview

Erythema nodosum is a type of inflammation that affects the fat tissue, commonly seen in adult females. It has a higher incidence rate in women, with a female to male ratio of up to three to one. On the other hand, sarcoidosis is a disease that affects multiple systems in the body, characterized by the formation of granulomas. It is more prevalent in adults aged 20-40, with acute cases more common in white patients and chronic cases more common in Afro-Caribbean patients.

Around 30% to 40% of erythema nodosum cases are associated with sarcoidosis. To confirm the diagnosis, chest x-ray, high-resolution CT, and transbronchial biopsy are the main investigations employed. Corticosteroids are the primary treatment for both erythema nodosum and sarcoidosis. With proper management, patients can achieve a good prognosis and quality of life.

According to NICE guidelines, oral antibiotics should only be prescribed in cases of acute exacerbation of COPD if there is purulent sputum or clinical signs of pneumonia. As this patient doesn’t exhibit these symptoms, prescribing oral antibiotics is not recommended.

Instead, increasing the frequency of inhaled bronchodilators is a suitable step in managing this patient’s acute exacerbation of COPD. The patient’s mild wheeze should improve with this treatment.

NICE recommends a review in 6 weeks if there is no rapid or significant worsening of symptoms. However, if symptoms worsen rapidly or significantly, the patient should be reviewed sooner by the appropriate healthcare provider.

Prescribing oral steroids is appropriate for managing this patient’s acute exacerbation of COPD as it can reduce inflammation and improve symptoms.

It is also appropriate to discuss smoking cessation with the patient, as they are still smoking. However, it should be documented if the patient is not interested in considering smoking cessation. Any opportunity for smoking cessation advice should be utilized.

Acute exacerbations of COPD are a common reason for hospitalization in developed countries. The most common causes of these exacerbations are bacterial infections, such as Haemophilus influenza, Streptococcus pneumoniae, and Moraxella catarrhalis, as well as respiratory viruses, with human rhinovirus being the most important pathogen. Symptoms of an exacerbation include an increase in dyspnea, cough, and wheezing, as well as hypoxia and acute confusion in some cases.

NICE guidelines recommend increasing the frequency of bronchodilator use and giving prednisolone for five days. Antibiotics should only be given if sputum is purulent or there are clinical signs of pneumonia. Admission to the hospital is recommended for patients with severe breathlessness, acute confusion or impaired consciousness, cyanosis, oxygen saturation less than 90%, social reasons, or significant comorbidity.

For severe exacerbations requiring secondary care, oxygen therapy should be used with an initial saturation target of 88-92%. Nebulized bronchodilators, such as beta adrenergic agonists and muscarinic antagonists, should also be used. Steroid therapy and IV theophylline may be considered, and non-invasive ventilation may be used for patients with type 2 respiratory failure. BiPAP is typically used with initial settings of EPAP at 4-5 cm H2O and IPAP at 10-15 cm H2O.

Referral and Assessment Guidelines for Lung Cancer

Persistent haemoptysis, superior vena caval obstruction, and stridor are all red flags for possible lung cancer and require immediate referral to a cancer specialist. In addition, NICE NG12 recommends an urgent chest X-ray within two weeks for individuals aged 40 and over who have unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss, especially if they have a history of smoking. For those with persistent or recurrent chest infections, finger clubbing, supraclavicular or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or thrombocytosis, an urgent chest X-ray should also be considered. Early detection and referral can improve outcomes for individuals with lung cancer.

Consideration of Alpha 1-Antitrypsin Deficiency in a Young Smoker with COPD

This patient’s young age, symptoms, chest x-ray findings, and spirometry results suggest the possibility of alpha 1-antitrypsin deficiency, a genetic condition that can cause pulmonary disease and liver disease. As a smoker, this patient is at increased risk for COPD, but the early onset of the disease raises suspicion for an underlying genetic cause. Additionally, the family history supports the consideration of alpha 1-antitrypsin deficiency, which is inherited in an autosomal dominant pattern.

To confirm the diagnosis, serum alpha 1-antitrypsin levels would be the most appropriate blood investigation. Other blood tests, such as ACE levels for sarcoidosis, copper and ceruloplasmin levels for Wilson’s disease, ferritin levels for hemochromatosis, and rheumatoid factor for rheumatoid arthritis, are not likely to be helpful in this case.

It is important to consider alpha 1-antitrypsin deficiency in young patients with COPD, especially those with a family history of the condition. Early diagnosis and treatment can help prevent further lung and liver damage.

Investigating and Diagnosing COPD

To diagnose COPD, NICE recommends considering patients over 35 years of age who are smokers or ex-smokers and have symptoms such as chronic cough, exertional breathlessness, or regular sputum production. The following investigations are recommended: post-bronchodilator spirometry to demonstrate airflow obstruction, chest x-ray to exclude lung cancer and identify hyperinflation, bullae, or flat hemidiaphragm, full blood count to exclude secondary polycythaemia, and BMI calculation. The severity of COPD is categorized using the FEV1, with Stage 1 being mild and Stage 4 being very severe. Measuring peak expiratory flow is of limited value in COPD as it may underestimate the degree of airflow obstruction. It is important to note that the grading system has changed following the 2010 NICE guidelines, with Stage 1 now including patients with an FEV1 greater than 80% predicted but a post-bronchodilator FEV1/FVC ratio less than 70%.

Initial Management for COPD

The most appropriate initial management for COPD would be a short acting beta agonist or a short acting muscarinic antagonist. According to the Guidelines in Practice summary, a LAMA+LABA combination should be offered to people with spirometrically confirmed COPD who do not have asthmatic features or steroid responsiveness and remain breathless or have exacerbations despite other treatments. LABA+ICS should be considered for those with asthmatic features or steroid responsiveness. Antitussive therapy is not recommended, but a mucolytic can be considered for those with a chronic productive cough. In this breathless patient, a short acting muscarinic antagonist is the better choice. By optimizing non-pharmacological management and relevant vaccinations, patients can improve their symptoms and quality of life.

To ensure effective use of an inhaler, it is important to follow proper technique. Asthma UK provides helpful guidance on inhaler usage for different types of inhalers.

For a pressurised metered dose inhaler, it is advised to hold your breath for 10 seconds after inhaling the medication. This allows sufficient time for the medication to reach the airways, rather than being exhaled prematurely.

To use the inhaler, breathe in slowly and steadily while pressing down on the canister in one smooth motion. If a second dose is needed, wait for about 30 seconds before repeating to avoid any interference with the delivery of the medication.

Proper Inhaler Technique for Metered-Dose Inhalers

Metered-dose inhalers are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, it is important to use them correctly to ensure that the medication is delivered effectively to the lungs. Here is a step-by-step guide to proper inhaler technique:

1. Remove the cap and shake the inhaler.

2. Breathe out gently.

3. Place the mouthpiece in your mouth and begin to breathe in slowly and deeply.

4. As you start to inhale, press down on the canister to release the medication. Continue to inhale steadily and deeply.

5. Hold your breath for 10 seconds, or as long as is comfortable.

6. If a second dose is needed, wait approximately 30 seconds before repeating steps 1-5.

It is important to note that inhalers should only be used for the number of doses specified on the label. Once the inhaler is empty, a new one should be started. By following these steps, patients can ensure that they are using their inhaler correctly and receiving the full benefits of their medication.

The patient is currently in a room with normal air temperature, measuring 38.9º. Their blood pressure is 130/84 mmHg and they appear to be distressed, but not confused. Initial tests indicate that their hemoglobin level is 134 g/l and their platelet count is currently unknown.

Pneumonia is a serious respiratory infection that requires prompt assessment and management. In the primary care setting, the CRB65 criteria are used to stratify patients based on their risk of mortality. Patients with a score of 0 are considered low risk and may be treated at home, while those with a score of 3 or 4 are high risk and require urgent admission to hospital. Antibiotic therapy should be considered based on the patient’s CRP level. In the secondary care setting, the CURB65 criteria are used, which includes an additional criterion of urea > 7 mmol/L. Chest x-rays and blood and sputum cultures are recommended for intermediate or high-risk patients. Management of low-severity pneumonia typically involves a 5-day course of amoxicillin, while moderate to high-severity pneumonia may require dual antibiotic therapy for 7-10 days. Discharge criteria and advice post-discharge are also provided, including information on expected symptom resolution and the need for a repeat chest x-ray at 6 weeks.

Referral to a respiratory specialist is recommended for patients who are suspected to have occupational asthma.

Occupational Asthma: Causes and Symptoms

Occupational asthma is a type of asthma that is caused by exposure to certain chemicals in the workplace. Patients may experience worsening asthma symptoms while at work or notice an improvement in symptoms when away from work. The most common cause of occupational asthma is exposure to isocyanates, which are found in spray painting and foam moulding using adhesives. Other chemicals associated with occupational asthma include platinum salts, soldering flux resin, glutaraldehyde, flour, epoxy resins, and proteolytic enzymes.

To diagnose occupational asthma, it is recommended to measure peak expiratory flow at work and away from work. If there is a significant difference in peak expiratory flow, referral to a respiratory specialist is necessary. Treatment may include avoiding exposure to the triggering chemicals and using medications to manage asthma symptoms. It is important for employers to provide a safe working environment and for employees to report any concerns about potential exposure to harmful chemicals.

Spirometry and Management of COPD

In spirometry, a ratio of FEV1/FVC less than 0.7 indicates the presence of chronic obstructive pulmonary disease (COPD). A diagnosis of stage 3 (severe) COPD is made when FEV1 is between 30-49% predicted. Smoking cessation is crucial in managing COPD. If a person prescribed with a short-acting beta-2 agonist (SABA) or short-acting muscarinic antagonist (SAMA) remains breathless or experiences exacerbations, a long-acting beta-2 agonist (LABA) or long-acting muscarinic antagonist (LAMA) should be offered. It is recommended to discontinue treatment with a SAMA if prescribing a LAMA. A regular LAMA is preferred over a regular SAMA four times daily. It is important to note that this approach differs from the PCRS approach, which categorizes treatment based on phenotypic groups for patients with predominant breathlessness, exacerbations, or COPD with asthma.

Patients who have been diagnosed with anaphylaxis should be referred to a specialist allergy clinic for proper management. In the case of this boy, specialist input and education for his caregivers and school may be necessary. Prescribing a 300 microgram adrenaline injector is not recommended as it is the incorrect dose for his age. Instead, he should be given two 150 microgram adrenaline injectors with appropriate training provided. Referral for patch testing may not be sufficient as more rigorous follow-up is needed after anaphylaxis. Regular antihistamines may be necessary if ongoing symptoms such as urticaria are present, but this is not indicated in the question.

Anaphylaxis is a severe and potentially life-threatening allergic reaction that affects the entire body. It can be caused by various triggers, including food, drugs, and insect venom. The symptoms of anaphylaxis typically develop suddenly and progress rapidly, affecting the airway, breathing, and circulation. Swelling of the throat and tongue, hoarse voice, and stridor are common airway problems, while respiratory wheeze and dyspnea are common breathing problems. Hypotension and tachycardia are common circulation problems. Skin and mucosal changes, such as generalized pruritus and widespread erythematous or urticarial rash, are also present in around 80-90% of patients.

The most important drug in the management of anaphylaxis is intramuscular adrenaline, which should be administered as soon as possible. The recommended doses of adrenaline vary depending on the patient’s age, with the highest dose being 500 micrograms for adults and children over 12 years old. Adrenaline can be repeated every 5 minutes if necessary. If the patient’s respiratory and/or cardiovascular problems persist despite two doses of IM adrenaline, IV fluids should be given for shock, and expert help should be sought for consideration of an IV adrenaline infusion.

Following stabilisation, non-sedating oral antihistamines may be given to patients with persisting skin symptoms. Patients with a new diagnosis of anaphylaxis should be referred to a specialist allergy clinic, and an adrenaline injector should be given as an interim measure before the specialist allergy assessment. Patients should be prescribed two adrenaline auto-injectors, and training should be provided on how to use them. A risk-stratified approach to discharge should be taken, as biphasic reactions can occur in up to 20% of patients. The Resus Council UK recommends a fast-track discharge for patients who have had a good response to a single dose of adrenaline and have been given an adrenaline auto-injector and trained how to use it. Patients who require two doses of IM adrenaline or have had a previous biphasic reaction should be observed for a minimum of 6 hours after symptom resolution, while those who have had a severe reaction requiring more than two doses of IM adrenaline or have severe asthma should be observed for a minimum of 12 hours after symptom resolution. Patients who present late at night or in areas where access to emergency care may be difficult should also be observed for a minimum of 12

Understanding Asbestos Exposure and Mesothelioma

Asbestos is a group of minerals that occur naturally in the environment as bundles of fibres. Exposure to asbestos can lead to various health problems, including asbestosis, lung cancer, mesothelioma, and other cancers. Smokers who are also exposed to asbestos have a higher risk of developing lung cancer. If you suspect that you have been exposed to asbestos, it is important to inform your physician and report any symptoms.

Mesothelioma is a type of cancer that is commonly associated with asbestos exposure. Symptoms of mesothelioma may include chest pain, breathlessness, weight loss, fatigue, and sweats. In some cases, there may be evidence of effusion or pleural thickening on a chest X-ray. An occupational history is important in identifying potential exposure to asbestos.

According to NICE guidelines, individuals aged 40 and over who have unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss should be offered an urgent chest X-ray within two weeks to assess for mesothelioma. This is especially important for those who have been exposed to asbestos or have a history of smoking. Early detection and treatment can improve outcomes for those with mesothelioma.

Superior Vena Caval Obstruction (SVCO)

Superior Vena Caval Obstruction (SVCO) is a condition where there is a blockage of blood flow in the superior vena cava. This can be caused by external compression or thrombosis within the vein. The most common cause of SVCO is malignancy, particularly lung cancer and lymphoma. Benign causes include intrathoracic goitre and granulomatous conditions such as sarcoidosis.

The typical features of SVCO include facial and upper body oedema, facial plethora, venous distention, and increased shortness of breath. Other symptoms may include dizziness, syncope, and headache due to pressure effect. This gentleman is an ex-smoker and has a persistent productive cough that has not responded to repeated antibiotic use, which is suspicious of an underlying lung malignancy.

Prompt recognition of SVCO on clinical grounds is crucial, and immediate referral for specialist assessment is necessary. If there is any stridor or laryngeal oedema, SVCO becomes a medical emergency.